Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 20/20 | 1.00 |
| ▸ | CMA1 | P23946 | 19/20 | 1.00 |
| ▸ | CTSG | P08311 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556119 | 0.90 | CTRC (1.00) | CTRCCMA1CTSG | |
| SCHEMBL8605012 | 0.90 | CTRC (1.00) | CTRCCMA1CTSG | |
| SCHEMBL7157284 | 0.85 | CMA1 (0.74) | CTRCCMA1CTSG | |
| SCHEMBL6558180 | 0.85 | CTRC (0.82) | CTRCCMA1CTSG | |
| SCHEMBL6556271 | 0.85 | CTRC (1.00) | CTRCCMA1 | |
| SCHEMBL6558220 | 0.85 | CTRC (0.91) | CTRCCMA1CTSG | |
| SCHEMBL6556352 | 0.84 | CTRC (1.00) | CTRCCMA1 | |
| SCHEMBL6558267 | 0.83 | CTRC (1.00) | CTRCCMA1 | |
| SCHEMBL6558270 | 0.83 | CTRC (1.00) | CTRCCMA1 | |
| SCHEMBL6556475 | 0.83 | CTRC (1.00) | CTRCCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528514-B1 | Pyrimidin-4-one-5-amino-3-alkylcarboxamidomethyl compounds | WELFIDE CORPORATION (JP) | 2003-03-04 | — | — | US | claimed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-6528514-B1 | Pyrimidin-4-one-5-amino-3-alkylcarboxamidomethyl compounds | WELFIDE CORPORATION (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1062949-A1 | IgE ANTIBODY PRODUCTION INHIBITORS AND AUTOIMMUNE DISEASES INHIBITORS | Welfide Corporation (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CTRC 843/4885CMA1 313/4885CTSG 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.